NEW YORK, June 5 - Xerion Pharmaceuticals has agreed to license Cambridge Antibody Technology's library of human phage antibodies for use in drug discovery and functional proteomics, the companies said Tuesday.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.